Question normal

I'd like to congratulate the authors on their achievement with this publication. This will open up a whole new world of treatment paradigms for patients that present outside the original "thrombolysis window". I had one question that I'd like to ask.

In clinical practice, from my experience, if a patient presents outside the thrombolysis window (> 4.5 hours), in most cases, an anti-platelet (such as aspirin) is commenced. This study compared alteplase with placebo; do you think the results would be reproducible if alteplase was compared with perhaps aspirin or another anti-platelet?